Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
6,498 people get CELG articles and Market Currents by email alert.
Get email alerts on CELG »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Business Wire (Apr 29, 2013)
-
-
-
-
-
Business Wire (Apr 25, 2013)
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Celgene Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Celgene Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Celgene's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Celgene Management Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012 • 1 Comment
-
Celgene Corporation - Shareholder/Analyst CallMon, Dec 12, 2011
-
Celgene Management Discusses Q3 2011 Results - Earnings Call TranscriptThu, Oct 27, 2011
-
Celgene Management Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Celgene's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 28, 2011 • 2 Comments
-
Celgene's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Jan 27, 2011
-
Celgene CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Oct 28, 2010
-
Celgene Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Celgene Q1 2010 Earnings Call TranscriptFri, Apr 30, 2010
-
Celgene Corporation Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Celgene Corporation Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Celgene Corporation Q2 2009 Earnings Call TranscriptThu, Jul 23, 2009
-
Celgene Corporation Q1 2009 Earnings Call TranscriptThu, Apr 30, 2009
-
at MarketWatch.com (Thu, 4:28PM)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at Fox Business (May 2, 2013)
-
Business Wire (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 19, 2013)
-
at CNBC.com (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 3, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at Fox Business (Apr 1, 2013)
CELG vs. ETF Alternatives
Company Description
Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
- Thursday, April 25, 8:01 AM More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B. ABRAXANE sales of $123M and VIDAZA of $204M inline. SG&A expenses of $333M, +11.3%. Purchased approximately 4.2M shares at cost of $403M (average price $95.95). FY2013 EPS guidance raised to $5.55-$5.65 from $5.50-$5.60. Shares -0.9% premarket. Conference call at 9 ET. (PR) Comment! [Healthcare, On the Move, Earnings]
- Monday, April 22, 8:02 AM Celgene (CELG) +1.8% premarket as Cantor Fitzgerald reiterates the stock a Buy and raises its price target to $142. Comment! [Healthcare, On the Move]
- Friday, April 5, 8:13 AM Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket. 2 Comments [Healthcare, On the Move]
- Wednesday, February 20, 8:45 AM Celgene (CELG +1.8%) agrees to buy back $600M in stock from an investment bank as part of its repurchase program. So far this year, the company has bought back $385M in shares and has $1.45B remaining in the scheme. Celgene has repurchased $5.05B of stock over the past four years. 1 Comment [Healthcare, On the Move]
- Thursday, January 24, 2:23 PM Celgene (CELG -1%) slips after posting a lackluster Q4 report, with earnings matching analyst expectations while revenue falls just short of estimates. The company reaffirms its FY13 outlook with revenue just shy of expectations, expecting to earn between $5.50 to $5.60 a share with 11% sales growth on around $6B in sales. The Street is looking for an EPS of $5.64 on $6.1B in revenue. 4 Comments [Healthcare, On the Move, Earnings]
- Wednesday, January 23, 2:43 PM Threshold Pharmaceuticals (THLD +18%) soars after Celgene (CELG -0.7%) reported positive Phase III data for Abraxane, its prospective treatment for pancreatic cancer, but the data came in slightly below analysts' expectations. Stifel Nicolaus reiterated a Buy on THLD after the news, saying that its own treatment will be more competitive with CELG's product. Comment! [Healthcare, On the Move]
- Monday, January 7, 2:32 PM Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the higher end of previous estimates and in-line results for 2013. Net product sales are expected to double between 2013 and 2017, reaching over $12B, with numerous milestones expected in 2013 for three "potential blockbuster" drugs. One of the drugs is its existing cancer drug Abraxane, which it hopes to have approved as a treatment for pancreatic cancer - which is among the hardest to treat - sometime this year. Comment! [Healthcare, On the Move]
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Monday, November 12, 2012, 8:44 AM In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors. 1 Comment [Healthcare, On the Move]
- Thursday, October 25, 2012, 7:41 AM Celgene (CELG): Q3 EPS of $1.29 beats by $0.02. Revenue of $1.42B (+14% Y/Y) in-line. Shares +1.3% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, September 10, 2012, 2:10 PM Celgene (CELG -2.5%) slides on a UBS downgrade to Neutral on valuation this morning. The firm cites a lack of significant upside to its anemia drug Revlimid, saying the story has already "played itself out" since approval for the drug was shot down in the European Union. 2 Comments [Healthcare, On the Move]
- Thursday, July 26, 2012, 9:44 AM More on Celgene (CELG +5.1%) Q2: net profit $367M vs. $279M a year earlier; sales of Revlimid, its multiple myeloma cancer drug, +17% to $934M. Increases FY EPS outlook to $4.80-$4.85 from previous forecast of $4.70-$4.80. Reiterates revenue guidance of around +15% to $5.4B-$5.6B. Consensus is for $4.80 and $5.45B. Comment! [Earnings, On the Move, Healthcare]
- Tuesday, July 24, 2012, 11:23 AM Dendreon (DNDN) +6.9% - although down from earlier highs - on rumors it might be trying to sell itself, with Celgene (CELG -0.2%) one name being mooted. Feeding the speculation beast is new CEO John Johnson working from New Jersey even though the company is based in Seattle. 6 Comments [On the Move, Healthcare]
- Friday, June 29, 2012, 2:07 PM Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's reiterated guidance following the Revlimid setback. Comment! [Healthcare, On the Move]
- Thursday, June 21, 2012, 11:19 AM SA contributor Valuentum joins Bernstein in defending Celgene (CELG -11.9% to $59.15), which is hurting badly following its EU Revlimid bombshell today. Valuentum says the share is undervalued and is attractive at below $65. "Firms that generate a free cash flow margin above 5% are usually considered cash cows." Celgene's 3-year average is 30.6% . Comment! [Healthcare, On the Move]
-
Capitalist Bull
Leading growth stocks taking a break while the $ES_F shows no signs of fatigue. http://stks.co/qD73 $NFLX $REGN $SPWR $GOOG $CELG $NSM - View all 0 replies
-
The Wall Street Transcript
Celgene Corporation ($CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane- http://su.pr/1wgenU - View all 0 replies
-
Holly Thompson
Celgene $CELG reports Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B. - View all 0 replies
-
- View all 4 replies
-
-
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
-
Jim Van Meerten
$CELG - 100% Barchart technical buy signals - 8 new highs and up 10.24% in the last month - Relative strength Index 78.63% - View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 5 2013 | $CELG $FB $FFIV $NIHD $RDWR | SharePlanner http://bit.ly/17gVXmw - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 4 replies
-
-
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
-
StockBeaver
According to my analysis, $CELG has been overbought since Jan 7th. I like the company... Analysis: http://bit.ly/YkcTGM - View all 4 replies
-
StockBeaver: I'm working on this feature of allowing users to 'Search'. Two challenges: 1. The site is currently optimized for reads. It's zippy!
-
StockBeaver: The 2nd issue is that any input field on a website is window for hackers. Currently stockbever.com has 0 input fields.
-
- View all 2 replies
-
-
-
Chimera Research Group
$CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs - View all 1 replies
-
-
The Scientist
CELG Abraxane P3 panc ca studies likely to be a bust. Trial began 3/09; near end of trial 9/11, had to add 210 pts to the study - View all 2 replies
-
The Scientist: Only logical reason to add more pts was that OS data was weak; more pts were needed to raise OS data
-
-
The Scientist
Awaiting CELG Abraxane data on panc CA. SPARC hypothesis controversial. Abrax does not improve OS in breast CA, which is usually SPARC+. - View all 2 replies
-
The Scientist: Perhaps destroying SPARC/stroma promotes metastasis - allows for easier malignant cell escape. Abrax should have worked better in breast CA.
-
-
- View all 1 replies
-
-
- View all 1 replies
-
blablah: Do not understand the reason for such a big drop. Revlimid's usage is ever increasing and the withdrawal was only for certain strength
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 5 replies
-
-
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
-
- View all 1 replies
-
Oceanstats: I feel you pain...sold DANG yesterday after soaring.....soaring even more today! DANG IT!
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 4 replies
-
0ZJ: ...I'm thinking I was at least a day earlier. Per my indicators I could short again today. Comtemplating it.
-
ker.nulov@gmail.com: I mean, when current month's (high - low) value is inside previous month's (high-low) which usually means that no trend change happened.
-
- View all 1 replies
-